Nano-X Imaging Ltd.
NASDAQ:NNOXMedical - Devices
-$0.03 today
- Market cap
- $50.94M
- Beta
- 1.17
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$1.12
Volume 0.52M
Average 1.46M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Nano-X Imaging Ltd.
NASDAQ:NNOX
Intrinsic Alpha fair value
Locked
Current Price
$0.73
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +14.9% | +47.0% (5yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +14.9% over three years. Forward estimates point to Revenue at +47.0% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Perspective Therapeutics, Inc. AMEX:CATX | $320.47M | $2.81 | Not rated | -0.0 | -63.02% |
TriSalus Life Sciences, Inc. NASDAQ:TLSI | $287.25M | $4.67 | Not rated | -7.4 | -56.15% |
Profound Medical Corp. NASDAQ:PROF | $216.94M | $5.97 | Not rated | -6.3 | +12.07% |
Inogen, Inc. NASDAQ:INGN | $143.77M | $5.31 | Not rated | -7.0 | -17.75% |
Solana Company NASDAQ:HSDT | $129.62M | $2.22 | Not rated | -0.9 | -48.92% |
Health Catalyst, Inc. NASDAQ:HCAT | $125.62M | $1.70 | Undervalued | -0.5 | -36.45% |
MaxCyte, Inc. NASDAQ:MXCT | $124.26M | $1.16 | Not rated | -3.2 | -21.47% |
Quanterix Corporation NASDAQ:QTRX | $120.59M | $2.56 | Not rated | -1.5 | -65.65% |
Outset Medical, Inc. NASDAQ:OM | $59.50M | $3.21 | Not rated | -1.2 | -34.46% |
SANUWAVE Health, Inc. NASDAQ:SNWV | $35.26M | $4.10 | Undervalued | 5.0 | -81.50% |
Continue the stock analysis
Jump to another research area for this company.